Clinical Trial Update: ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D [Phase 3]

View source ↗

Summary

ALTTO is a Phase 3 trial evaluating adjuvant lapatinib and/or trastuzumab in breast cancer; results were completed and posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lapatinib (Tykerb) (lapatinib)
• Trastuzumab (Herceptin) (trastuzumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neoplasms, Breast | Phase 3 | Status: COMPLETED | Results posted: 2014-08-18